🏛️ Verified NIH Record • Updated 2026-03-11
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (NCT02886065)
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Massachusetts General Hospital
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma. The following intervention will be involved in this study: * Lenalidomide * Citarinostat (CC-96241) * PVX-410
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Weill Cornell Medical College — New York, New York
- Duke University Medical Center — Durham, North Carolina
- University Hospital of Cleveland- Seidman Cancer Center — Cleveland, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Smoldering Multiple Myeloma
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — Tampa, Florida
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma — Rochester, New York
- Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial — Salt Lake City, Utah
- Screening for AL Amyloidosis in Smoldering Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Smoldering Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.